How Mukunda was paid
$568,000 in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Total |
|---|---|---|
| Ram MukundaPresident and CEO | $396,000 | $568,000 |
| Claudia GrimaldiVice President, CCO, and PFO | $226,000 | $259,000 |
What changed and why
- $568K$568,000: Ram Mukunda’s total compensation fell from $1,821,000 in fiscal 2024.
- $92,000$92,000: Mukunda received a fiscal 2025 bonus; approximately $423,000 of outstanding bonus was converted into performance-based bonuses.
- Dashes: No stock awards were reported for either named executive in fiscal 2025.
- $5MTwo milestones govern converted bonuses: CALMA Phase 2 completion and fundraising of at least $5 million.
- Operational metrics include drug development, pipeline progress, R&D spending, regulatory compliance, partnerships, and financial health.
- $203K$203,000 negative: Mukunda’s compensation actually paid reflected a substantial decline in equity values.
Other IGC Pharma proxy statements
- 2026 proxy statement
Ram Mukunda paid $1.9M (+233% on the year).
Filed Oct 22, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.